Oppenheimer Cuts Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $54.00

Corbus Pharmaceuticals (NASDAQ:CRBP) had its price target reduced by Oppenheimer from $57.00 to $54.00 in a research note published on Wednesday,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently commented on the company. Jefferies Financial Group reduced their target price on Corbus Pharmaceuticals from $36.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Monday, April 20th. Wall Street Zen raised Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Finally, Guggenheim reaffirmed a “buy” rating and set a $45.00 target price on shares of Corbus Pharmaceuticals in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, Corbus Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $42.33.

Corbus Pharmaceuticals Stock Down 7.9%

CRBP stock opened at $11.03 on Wednesday. Corbus Pharmaceuticals has a 52-week low of $6.72 and a 52-week high of $20.56. The stock’s 50 day moving average is $9.90 and its two-hundred day moving average is $9.64. The company has a market capitalization of $204.39 million, a PE ratio of -1.90 and a beta of 2.68.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.03. As a group, sell-side analysts anticipate that Corbus Pharmaceuticals will post -4.83 EPS for the current year.

Institutional Trading of Corbus Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. Orbimed Advisors LLC lifted its holdings in shares of Corbus Pharmaceuticals by 8.8% in the 1st quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company’s stock worth $16,313,000 after purchasing an additional 140,000 shares during the last quarter. Rangeley Capital LLC acquired a new stake in Corbus Pharmaceuticals in the 1st quarter valued at approximately $421,000. Pale Fire Capital SE increased its position in Corbus Pharmaceuticals by 14.5% in the 1st quarter. Pale Fire Capital SE now owns 21,350 shares of the biopharmaceutical company’s stock valued at $200,000 after acquiring an additional 2,700 shares during the period. Dimensional Fund Advisors LP increased its position in Corbus Pharmaceuticals by 76.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 136,602 shares of the biopharmaceutical company’s stock valued at $1,281,000 after acquiring an additional 59,248 shares during the period. Finally, Seven Fleet Capital Management LP acquired a new stake in Corbus Pharmaceuticals in the 4th quarter valued at approximately $462,000. Institutional investors own 64.64% of the company’s stock.

Key Corbus Pharmaceuticals News

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Corbus appointed pharma veteran Brent Pfeiffenberger, PharmD, MBA, to its Board of Directors, a move that could strengthen strategy and governance at the clinical-stage biotech. Article: Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
• Positive Sentiment: Several analysts at HC Wainwright raised longer-term EPS estimates for CRBP, including FY2026, FY2027, FY2028, FY2029 and FY2030, suggesting improving expectations over time. Article: Corbus Pharmaceuticals Holdings, Inc. analyst estimates
• Neutral Sentiment: Lifesci Capital also published new earnings forecasts for Q2, Q3, Q4 and FY2026, but the estimates still point to continued losses, so the near-term impact on the stock is unclear. Article: Corbus Pharmaceuticals Holdings, Inc. analyst estimates
• Negative Sentiment: Even after some upward revisions, analysts still expect Corbus to remain unprofitable for several years, with EPS forecasts remaining deeply negative in the near term, which can weigh on biotech valuations. Article: Corbus Pharmaceuticals Holdings, Inc. analyst estimates

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.